People
Biopharmaceutical companies need to look beyond the usual targets when addressing neurodegenerative disorders and also must work to correlate genetic changes to cognitive changes in patients, according to panelists at BIO’s on-demand session, “Battle of the Brains: Rethinking Neurodegenerative Disease Treatment.”
The primary endpoint of the trial will be prevention of symptomatic COVID-19 disease, with key secondary endpoints including prevention of severe COVID-19, defined as hospitalization, and prevention of infection by SARS-CoV-2.
According to the report, at least 17 of this year’s 28 new drug shortages “are directly or indirectly prompted by events the current COVID-19 pandemic has brought on,” which includes the increased demand for anesthetics and other drugs used to facilitate intubation.
In an interview this morning with CNN, Dr. Anthony Fauci said the government will help finance Phase III studies of three vaccine candidates.
Biogen announced new data from the NURTURE trial of pre-symptomatic patients with spinal muscular atrophy (SMA).
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 10, 2020.
Charles Lieber, the former chair of Harvard University’s Chemical Biology Department, was indicted by a federal grand jury this week on two counts of making false statements.
Fauci, a longtime infectious disease expert, said COVID-19 is the stuff of nightmares in the way it has quickly spread across the globe, infected millions of people and contributed to the deaths of more than 408,000 people.
The healthcare system is innovating to address the pain points the pandemic revealed. Specifically, it is becoming more proactive, preventative and personalized.
One day, cell and gene therapies will be as common as small molecules and antibody-based therapies are today, according to panelists at BIO’s June 8 virtual session, “The Next Generation of Medicine: Cell Therapies, Gene Therapies and Beyond.”
PRESS RELEASES